CYP2A6- and CYP2A13-catalyzed Metabolism of the Nicotine Δ5'(1')iminium Ion

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 2012 Aug 8

PMID 22869927

Citations 14

Authors

Linda B von Weymarn

Cassandra Retzlaff

Sharon E Murphy

Affiliations

Soon will be listed here.

Abstract

Nicotine, the major addictive agent in tobacco, is metabolized primarily by CYP2A6-catalyzed oxidation. The product of this reaction, 5'-hydroxynicotine, is in equilibrium with the nicotine Δ5'(1')iminium ion and is further metabolized to cotinine. We reported previously that both CYP2A6 and the closely related extrahepatic enzyme CYP2A13 were inactivated during nicotine metabolism; however, inactivation occurred after metabolism was complete. This led to the hypothesis that oxidation of a nicotine metabolite, possibly the nicotine Δ5'(1')iminium ion, was responsible for generating the inactivating species. In the studies presented here, we confirm that the nicotine Δ5'(1')iminium ion is an inactivator of both CYP2A6 and CYP2A13, and inactivation depends on time, concentration, and the presence of NADPH. Inactivation was not reversible and was accompanied by a parallel loss in spectrally active protein, as measured by reduced CO spectra. These data are consistent with the characterization of the nicotine Δ5'(1')iminium ion as a mechanism-based inactivator of both CYP2A13 and CYP2A6. We also confirm that both CYP2A6 and CYP2A13 catalyze the metabolism of the nicotine Δ5'(1')iminium ion to cotinine and provide evidence that both enzymes catalyze the sequential metabolism of the nicotine Δ5'(1')iminium ion. That is, a fraction of the cotinine formed may not be released from the enzyme before further oxidation to 3'-hydroxycotinine.

Citing Articles

PharmVar GeneFocus: CYP2A6.

Langlois A, Chenoweth M, Twesigomwe D, Scantamburlo G, Whirl-Carrillo M, Sangkuhl K Clin Pharmacol Ther. 2024; 116(4):948-962.

PMID: 39051767 PMC: 11452280. DOI: 10.1002/cpt.3387.

Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD).

Nasrin S, Coates S, Bardhi K, Watson C, Muscat J, Lazarus P Chem Res Toxicol. 2023; 36(2):177-187.

PMID: 36626330 PMC: 9945182. DOI: 10.1021/acs.chemrestox.2c00259.

Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation.

Li H, Wang Q, Li S, Jia C Genet Res (Camb). 2022; 2022:2917881.

PMID: 36245555 PMC: 9534651. DOI: 10.1155/2022/2917881.

Nicotine Inhibits the Cytotoxicity and Genotoxicity of NNK Mediated by CYP2A13 in BEAS-2B Cells.

Sun Y, Wang H, Chen H, Zhang S, Li J, Zhang J Molecules. 2022; 27(15).

PMID: 35956805 PMC: 9369970. DOI: 10.3390/molecules27154851.

Biochemistry of nicotine metabolism and its relevance to lung cancer.

Murphy S J Biol Chem. 2021; 296:100722.

PMID: 33932402 PMC: 8167289. DOI: 10.1016/j.jbc.2021.100722.

References

Peterson L, Trevor A, Castagnoli Jr N . Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1'(5')-iminium species. J Med Chem. 1987; 30(2):249-54. DOI: 10.1021/jm00385a004. View

Jalas J, Hecht S, Murphy S . Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol. 2005; 18(2):95-110. DOI: 10.1021/tx049847p. View

Bloom J, Hinrichs A, Wang J, von Weymarn L, Kharasch E, Bierut L . The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics. 2011; 21(7):403-16. PMC: 3116045. DOI: 10.1097/FPC.0b013e328346e8c0. View

Chowdhury G, Calcutt M, Guengerich F . Oxidation of N-Nitrosoalkylamines by human cytochrome P450 2A6: sequential oxidation to aldehydes and carboxylic acids and analysis of reaction steps. J Biol Chem. 2010; 285(11):8031-44. PMC: 2832954. DOI: 10.1074/jbc.M109.088039. View

von Weymarn L, Blobaum A, Hollenberg P . The mechanism-based inactivation of p450 2B4 by tert-butyl 1-methyl-2-propynyl ether: structural determination of the adducts to the p450 heme. Arch Biochem Biophys. 2004; 425(1):95-105. DOI: 10.1016/j.abb.2004.03.014. View

von Weymarn L, Murphy S . CYP2A13-catalysed coumarin metabolism: comparison with CYP2A5 and CYP2A6. Xenobiotica. 2003; 33(1):73-81. DOI: 10.1080/0049825021000022302. View

Werle E, Meyer A . [Decomposition of tobacco alkaloids in animal tissue]. Biochem Z. 1950; 321(3):221-35. View

Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K . Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther. 1996; 277(2):1010-5. View

Hanna I, Teiber J, Kokones K, Hollenberg P . Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch Biochem Biophys. 1998; 350(2):324-32. DOI: 10.1006/abbi.1997.0534. View

10.

Kent U, Yanev S, Hollenberg P . Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by n-propylxanthate. Chem Res Toxicol. 1999; 12(4):317-22. DOI: 10.1021/tx9802421. View

11.

Yano J, Hsu M, Griffin K, Stout C, Johnson E . Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol. 2005; 12(9):822-3. DOI: 10.1038/nsmb971. View

12.

Denton T, Zhang X, Cashman J . Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem Pharmacol. 2004; 67(4):751-6. DOI: 10.1016/j.bcp.2003.10.022. View

13.

Shigenaga M, TREVOR A, Castagnoli Jr N . Metabolism-dependent covalent binding of (S)-[5-3H]nicotine to liver and lung microsomal macromolecules. Drug Metab Dispos. 1988; 16(3):397-402. View

14.

Gorrod J, Hibberd A . The metabolism of nicotine-delta 1'(5')-iminium ion, in vivo and in vitro. Eur J Drug Metab Pharmacokinet. 1982; 7(4):293-8. DOI: 10.1007/BF03189632. View

15.

Brown K, von Weymarn L, Murphy S . Identification of N-(hydroxymethyl) norcotinine as a major product of cytochrome P450 2A6, but not cytochrome P450 2A13-catalyzed cotinine metabolism. Chem Res Toxicol. 2005; 18(12):1792-8. DOI: 10.1021/tx0501381. View

16.

Su T, Bao Z, Zhang Q, Smith T, Hong J, Ding X . Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000; 60(18):5074-9. View

17.

Murphy S, Raulinaitis V, Brown K . Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos. 2005; 33(8):1166-73. DOI: 10.1124/dmd.105.004549. View

18.

Tuomi T, JOHNSSON T, Reijula K . Analysis of nicotine, 3-hydroxycotinine, cotinine, and caffeine in urine of passive smokers by HPLC-tandem mass spectrometry. Clin Chem. 1999; 45(12):2164-72. View

19.

Bao Z, He X, Ding X, Prabhu S, Hong J . Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos. 2004; 33(2):258-61. DOI: 10.1124/dmd.104.002105. View

20.

Soucek P . Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies. Arch Biochem Biophys. 1999; 370(2):190-200. DOI: 10.1006/abbi.1999.1388. View